TfR mAb-Cross-Linked Rituximab/MTX-PEG-PLL-PLGA Drug-Loaded Nanoparticles Enhance Anticancer Action in B Lymphocytes

• Main Authors: Ran Liu, Gang Zhao, Shujun Wang, Yan Gu, Qi Han, Baoan Chen
• Format: Article
• Language: English
• Published: Hindawi Limited 2019-01-01
• Series: Journal of Nanomaterials
• Online Access: http://dx.doi.org/10.1155/2019/7265450

Nanoparticles could enhance the drug targeted to the cancer cell by the enrichment of the drug levels, which leads to the improvement of the codelivery of both drugs for an antitumor effect. In the current study, we reported an efficient, local drug-loaded delivery strategy with a nanoparticle-loaded system. After the synthesis of Rituximab/MTX-PEG-PLL-PLGA, the transferrin receptor monoantibody (TfR mAb) was subsequently cross-linked to the nanoparticles. Compared to the traditional drug, the nanoparticle-loaded system can precisely and efficiently transport the Rituximab and Methotrexate (MTX) drug into SU-DHL-4 cells, a typical kind of B lymphocytes, which can significantly increase the cell apoptosis in the SU-DHL-4 cells. Thus, the multifunctional drug-loaded nanoparticles displayed the persistent stability and precise targeting properties, which enhanced the efficiency of anticancer efficiency in B lymphocytes.